Today: 20 July 2026
Browse Category

NASDAQ:BDRX 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

U.S. stock futures are edging higher early Wednesday as traders brace for the Federal Reserve’s final policy decision of 2025, with markets pricing in a high probability of another 25‑basis‑point rate cut. Futures on the Nasdaq 100, S&P 500 and Dow are modestly green, while the 10‑year U.S. Treasury yield hovers near 4.18% and commodities like silver trade at record highs above $61 an ounce. TipRanks+1
Go toTop